Oxford Events, the new replacement for OxTalks, will launch on 16th March. From now until the launch of Oxford Events, new events cannot be published or edited on OxTalks while all existing records are migrated to the new platform. The existing OxTalks site will remain available to view during this period.
From 16th, Oxford Events will launch on a new website: events.ox.ac.uk, and event submissions will resume. You will need a Halo login to submit events. Full details are available on the Staff Gateway.
Sebastian A. Brunemeier is a biotech founder and VC investor, focusing on the biology of ageing. Sebastian was previously a Principal at Apollo Health Ventures, the first and largest aging-focused venture capital fund in the world, as well as Co-Founder and Chief Investment Officer at Cambrian Biopharma, a biotech VC holding company focused on the biology of aging. Sebastian was CEO of Cyclone Therapeutics, a Scripps Research Institute spinout focused on proteostasis. He also was the founding EIR and COO of Samsara Therapeutics, focused on autophagy-enhancing small molecule drug discovery in Oxford, UK, which was recognized as ‘best startup’ at the Financial Times Pharma Conference. Prior to Apollo, he was a Fulbright Fellow in the biology of aging at the Gulbenkian Institute, awarded the Skaggs-Oxford fellowship at the Scripps Research Institute, and a SENS Foundation Scholar at the Buck Institute for Research on Aging. His education includes DPhil (PhD) training on the biochemistry of aging at the University of Oxford as a Clarendon Scholar, an MSc in Life Science Business Management and an MSc in Molecular Neuroscience from the University of Amsterdam as an Amsterdam Excellence Scholar. He served as a trustee of the British Society for Research on Aging and is an advisor to McKinsey & Company.
Surveying the underlying molecular and cellular neuroscience of brain ageing, in addition to a critique of currently fashionable themes in CNS drug discovery (with a focus on Alzheimer’s dementia).
